Company Encyclopedia
View More
name
Cellectar Bioscience
CLRB.US
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio.
1.935 T
CLRB.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Director John Neis Reports Disposal of Cellectar BioSciences Inc. Common Shares

    John Neis, Director at Cellectar BioSciences Inc., reported the disposal of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system. This AI-generated news brief by Public Technologies is for informational purposes only and not financial advice. The original content was published by Cellectar BioSciences Inc. on December 16, 2025.

    Reuters·
    US
    CLRB
    -7.25%
    Reuters·
    US
    CLRB
    -7.25%

    Cellectar Biosciences Announces Strategic Supply Agreement With Ionetix

    Dec 16 (Reuters) - Cellectar Biosciences Inc:* CELLECTAR BIOSCIENCES ANNOUNCES STRATEGIC SUPPLY AGREEMENT WITH IONETIX FOR ACTINIUM-225 AND ASTATINE-211 TO ADVANCE TARGETED ALPHA THERAPIES* CELLECTAR BIOSCIENCES INC - ANNOUNCES MULTI-YEAR SUPPLY AGREEMENT WITH IONETIX Source text: Further company coverage:

    Reuters·
    US
    CLRB
    -7.25%
    Reuters·
    US
    CLRB
    -7.25%

    Cellectar BioSciences Partners with Ionetix for Alpha-Emitting Isotope Supply

    Cellectar BioSciences Inc. has partnered with Ionetix Corporation in a multi-year agreement to secure supplies of alpha-emitting isotopes, Actinium-225 and Astatine-211, for cancer treatment development. This collaboration supports Cellectar's targeted alpha therapies, ensuring reliable isotope sources for drug development, clinical trials, and potential commercial launches. Ionetix's cyclotron technology will meet the growing demand for these isotopes as Cellectar advances its radiotherapeutic pipeline.

    Reuters·
    US
    CLRB
    -7.25%
    Reuters·
    US
    CLRB
    -7.25%

    Cellectar BioSciences Unveils Pipeline Advancements in Phospholipid Drug Conjugate Oncology Therapies

    Cellectar BioSciences Inc. announced advancements in its phospholipid drug conjugate platform, focusing on targeted radiotherapeutics for oncology. The company is ready for a Phase 1b/2a study for triple negative breast cancer and finalizing an IND application for CLR 225 in solid tumors. It aims for conditional market authorization in Europe and accelerated approval in the U.S. for iopofosine I 131. Cellectar plans further development and commercialization partnerships in the U.S. and EU.

    Reuters·
    US
    CLRB
    -7.25%
    Reuters·
    US
    CLRB
    -7.25%

    Cellectar Bioscience | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    CLRB
    -7.25%
    LB filings·
    US
    CLRB
    -7.25%
    © 2025 Longbridge｜Disclaimer